Evidence map›Paper›PMID 42513695›Full record

ReviewMaterials (Basel, Switzerland)2026

Emerging Nano Bioinks in Bioprinting: Functional Materials, Engineering Strategies, and Biomedical Applications.

Adam Mohammed, Hailey Gibbons, Thais Muratori Holanda, Nicole Salazar, Eric Saliim, Darlene K Taylor, Ufana Riaz

Abstract readReview
In one paragraph

Review in Materials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Adam MohammedJulius L. Chambers Biomedical/Biotechnology Research Institute (BBRI), North Carolina Central University, 1801 Fayetteville St., Durham, NC 27707, USA.
Hailey GibbonsJulius L. Chambers Biomedical/Biotechnology Research Institute (BBRI), North Carolina Central University, 1801 Fayetteville St., Durham, NC 27707, USA.
Thais Muratori HolandaJulius L. Chambers Biomedical/Biotechnology Research Institute (BBRI), North Carolina Central University, 1801 Fayetteville St., Durham, NC 27707, USA.
Nicole SalazarJulius L. Chambers Biomedical/Biotechnology Research Institute (BBRI), North Carolina Central University, 1801 Fayetteville St., Durham, NC 27707, USA.ORCID 0000-0002-8658-6553
Eric SaliimJulius L. Chambers Biomedical/Biotechnology Research Institute (BBRI), North Carolina Central University, 1801 Fayetteville St., Durham, NC 27707, USA.
Darlene K TaylorJulius L. Chambers Biomedical/Biotechnology Research Institute (BBRI), North Carolina Central University, 1801 Fayetteville St., Durham, NC 27707, USA.ORCID 0000-0002-6348-8336
Ufana RiazJulius L. Chambers Biomedical/Biotechnology Research Institute (BBRI), North Carolina Central University, 1801 Fayetteville St., Durham, NC 27707, USA.

Funding

Enhancing Biomedical Engineering, Imaging, and Technology Acceleration (BEITA) at North Carolina Central UniversityUG3EB037531 · NIBIB · NORTH CAROLINA CENTRAL UNIVERSITY · PI Nicole Salazar, Eric Saliim · 2025 to 2026
$856k
NIBIB NIH HHS UG3 EB037531
6 · The paper itself

Abstract

Nano bioinks have recently emerged as a promising class of biomaterials for advanced bioprinting applications, offering new opportunities in regenerative medicine, controlled drug delivery, and biosensing technologies. These materials are typically developed by integrating nanostructures such as nanoparticles, nanosheets, and nanofibers into polymeric or hydrogel matrices to enhance mechanical strength, bioactivity, and printing performance. Various fabrication approaches such as direct blending, in-situ polymerization, and surface functionalization are used to incorporate nanomaterials into bioink formulations. Subsequent crosslinking strategies are employed to improve print fidelity and structural stability while maintaining cell viability and biological functionality during the bioprinting process. Despite significant progress in recent years, several challenges continue to hinder the clinical translation of nano bioinks. Achieving consistent batch-to-batch reproducibility, ensuring long-term biocompatibility, and optimizing rheological properties for reliable printing remain critical issues. In addition, regulatory pathways and ethical considerations related to the biomedical use of nano-enabled bioinks are still insufficiently addressed in the literature. This review provides a comprehensive overview of recent advances in the design and fabrication of nano bioinks, highlighting key synthesis strategies, functional nanomaterials used in bioink formulations, and their emerging applications in tissue engineering, drug delivery, and biosensing. Furthermore, the review discusses the major technical, regulatory, and translational challenges that need to be addressed to facilitate the safe and effective implementation of nano bioinks in future biomedical applications.

Indexed as

biosensingdrug deliveryfabricationnano bioinksregenerative medicinetissue engineering

Identifiers

PMID42513695
PMCPMC13413337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.